Pneumotox Online
v2.2
  • RSS Feed
  • Contact
  • News
  • Diagnosing DIRD
  • Browse
  • Available on AppStore Available on AppStore

The Drug-Induced Respiratory Disease Website

Philippe Camus, M.D.

Dijon, France

  • Home
  • Browse by »
  • Drugs
  • Patterns

Alemtuzumab

1

XVII.b Opportunistic pulmonary/systemic infections

1
Last update : 31/12/2013
 
Search
Advanced search
Identify causative drugs
Diagnosing DIRD
1
Drug and radiation history
2
Drug singularity - Correct identification of the drug
3
Consistent timing of exposure v. onset of symptoms
4
Clinical, imaging, BAL, pathological pattern consistent with the specific drug
5
Careful exlusion of another cause
6
Remission of symptoms with removal of drug
7
Recurrence with rechallenge (rarely advisable)
8
Causality assessment
More detailed checklist

Publications

Risk of opportunistic infections in patients treated with alemtuzumab for multiple sclerosis.
Expert opinion on drug safety 2018 Jul;17;709-717 2018 Jul
Monoclonal antibody therapy for B-cell non-Hodgkin's lymphoma.
The New England journal of medicine 2008 Aug 07;359;613-26 2008 Aug 07
Rhodococcus equi infection after alemtuzumab therapy for T-cell prolymphocytic leukemia.
Emerging infectious diseases 2007 Dec;13;1942-3 2007 Dec
Efficacy and tolerability of alemtuzumab (CAMPATH-1H) in the salvage treatment of B-cell chronic lymphocytic leukemia--change of regimen needed?
Leukemia & lymphoma 2004 Feb;45;345-9 2004 Feb
Infectious toxicity using alemtuzumab.
Haematologica 2004 Dec;89;1415-9 2004 Dec

Powered by

  • ^
  • Contact
  • Cookies
  • About

The Pneumotox website uses cookies. By accessing or using our website, you consent to the collection, use and disclosure of the garnered information in accordance with our privacy policy.

Learn more about cookies